Summary

The 3-month reduction in HbA1c demonstrated by AGI-1067 is promising, but I still have many questions regarding the design and outcomes. There are many existing therapies that lower A1c - many have undesireable side effects like weight gain or hepatotoxicity.

Analysis

Lowering HbA1c by 0.5% at the highest dose makes for a good press release, but what was the starting level? There's a big difference between patients starting at 9.5% and those at 7.5%.

Also, I am troubled by the elevated liver enzyme results, even if they are sporadic. The most scary liver toxicities are those that are difficult to predict from a population genotype/phenotype standpoint. DPP-IV inhibitors like Januvia lower A1c by as much as 1.0% and don't appear to be hepatotoxic or cause weight gain. How will AGI-1067 compete with these?

Eric Gruff consults with leading institutions through GLG

Eric Gruff, Principal

What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Principal, E4 Consulting

 
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.